Operator independent left ventricular function monitoring during pharmacological stress echo with the new peak transcutaneous acceleration signal.

BACKGROUND: As the myocardium contracts isometrically, it generates vibrations that can be measured with an accelerometer. The vibration peak, peak endocardial acceleration (PEA), is an index of contractility. OBJECTIVE: To evaluate the feasibility of PEA measured by the cutaneous precordial application of the accelerometer sensor; and to assess the usefulness of PEA monitoring during pharmacological stress echocardiography. DESIGN: Feasibility study. SETTING: Stress echo laboratory. PATIENTS: 34 consecutive patients underwent pharmacological stress (26 with dipyridamole; 8 with dobutamine) and PEA monitoring simultaneously. INTERVENTIONS: A microaccelerometer was positioned in the precordial region and PEA was recorded. Dipyridamole was infused up to 0.84 mg/kg in 10 minutes, and dobutamine up to 40 microg/kg/min in 15 minutes. RESULTS: A consistent PEA signal was obtained in all patients. Overall mean (SD) baseline PEA was 0.26 (0.15) g (g = 9.8 m/s(2)), increasing to 0.5 (0.36) g at peak stress (+0.24 g, 95% confidence interval (CI) 0.14 to 0.34 g; p < 0.01). PEA increased from 0.26 (0.16) to 0.37 (0.25) g in the dipyridamole group (+0.11 g, 95% CI 0.08 to 0.16 g; p < 0.01), and from 0.29 (0.1) to 0.93 (0.37) g in the dobutamine group (+0.64 g, 95% CI 0.37 to 0.91 g; p < 0.01). CONCLUSIONS: Using precordial leads this method offers potential for diagnostic application in the short term monitoring of myocardial function. PEA monitoring is feasible during pharmacological stress and documents left ventricular inotropic response quantitatively in a non-invasive and operator independent fashion.

Detecting incipient vasovagal syncope: intraventricular acceleration.

The peak endocardial acceleration (PEA) caused by ventricular isometric contraction can be measured with an implantable microaccelerometer located inside the tip of a normal unipolar pacing lead. It has been shown that PEA correlates with myocardial contractility and the maximum rate of rise of ventricular pressure (peak dP/dt) of the left ventricle. A PEA measuring system was temporarily inserted into the apex of the right ventricle in seven patients affected by syncope of uncertain origin. Each patient subsequently underwent 60 degrees tilt testing with three different protocols: without pharmacological challenge (baseline); potentiated with sublingual trinitroglycerin (at a dose of 0.3 mg); and with isoproterenol infusion (at a dose of 3 micrograms/min). Each phase lasted 20 minutes. Syncope was induced in 1 patient during the baseline phase, in 3 patients during the trinitrin phase, and in 4 patients during the isoproterenol phase. Six patients had a negative response during the baseline phase and served as a control group. From the beginning of upright posture to the time of maximum heart rate, PEA increased by about the same amount in both positive and negative patients, but absolute values were from two- to three fold higher with isoproterenol (from 1.2 +/- 0.5 G to 1.6 +/- 0.8 G, from 0.8 +/- 0.2 G to 1.2 +/- 0.4 G, and from 2.8 +/- 1.8 G to 3.6 +/- 1.8 G, respectively, for negative, positive baseline or trinitrin, and positive isoproterenol tests). At the time of syncope, PEA values fell to baseline values. PEA changes were inversely correlated with blood pressure changes and directly correlated with heart rate changes. Thus, tilt induced syncope occurred both at low and high levels of left ventricular contractility. Whether spontaneous syncopes occur at low or high PEA behavior remains to be established. Since heart rate correlates well with changes in PEA and is far easier to measure, it is unlikely that a PEA measurement system or, in general, a contractility-based system, might become an ideal sensing parameter for the introduction of devices to combat vasovagal syncope.

Is local myocardial contractility related to endocardial acceleration signals detected by a transvenous pacing lead?

The availability of sensors monitoring cardiac function parameters may offer many interesting new applications in cardiac pacing. A microaccelerometer sensor (BEST, Biomechanical Endocardial Sorin Transducer) located at the tip of a pacing lead (PL) has been developed by Sorin Biomedica. The signal detected by the accelerometer, peak endocardial acceleration (PEA), was shown to reflect cardiac contractility and to be related to the dP/dt signal. Whether the PEA detected by the BEST sensor in different cardiac locations is the expression of local acceleration forces or reflects the whole heart contractility has not yet been demonstrated in humans. Endocardial acceleration and PEA were evaluated in five patients (4 males, 1 female, mean age 68 years) who underwent cardiac catheterization. Sinus rhythm was present in four patients and chronic atrial fibrillation was present in one. The BEST PL was introduced through the left subclavian vein and PEA signals were recorded: (1) at the apex of the right ventricle (RV), (2) within the coronary sinus (CS), (3) at the right atrial appendage (RAA), and (4) floating in the right atrium. The PEA signals were recorded simultaneously with surface ECG, intracardiac electrograms, and RV pressure. At each recording site, PEA signals with significant amplitude were always recorded during the preejection period, during the isovolumic contraction phase, independently of the recording site and cardiac rhythm. The PEA amplitude was higher in the RV (mean value 1.32 g) and it decreased in the RAA and CS (0.75 and 0.45 g, respectively). The same behavior of PEA was observed during sinus rhythm or atrial fibrillation. The amplitude and the timing of the PEA signals detected by the BEST accelerometer were independent of the recording site and atrial rhythm; they appeared to be strictly related to the global ventricular contractility. These results suggest that the BEST could be used either as an effective sensor in closed loop pacing systems, or primarily as a diagnostic hemodynamic sensor.

Mixed microprocessor-random logic approach for innovative pacing systems.

Modern pacing systems are becoming more and more sophisticated. Conversion of the information supplied by a sensor into suitable parameters for a rate controlling algorithm and the management of complex timing are common tasks for an integrated circuit (IC) in cardiac pacing. An effective solution consists of using a microprocessor to implement algorithms and pacing modes in a flexible way. The key point of using the same hardware resources for different tasks on a time sharing basis allows the design of a less complex IC when compared to a random logic structure with the same performances. The major design problems in a full microprocessor solution are its relatively low operating speed due to the low frequency clock necessary for low current drain, and the sequential structure of the machine itself. This can lead to unacceptable timing inaccuracy in all situations requiring the management of complex decision trees. In order to take full benefit from the advantages of a microprocessor structure without these drawbacks, a mixed microprocessor-random logic approach has been investigated. This architecture uses a microprocessor core to perform all high level nonreal-time operations (setup of the pacing cycle, data reduction and processing, data integrity checks) while a set of random logic peripherals is used for all critical timing aspects.

Pacemaker electrodes and problems related to cardiac pacing and sensing: current solutions and future trends.

The current status of cardiac electrical stimulation requires electrodes improvements both in pacing and sensing features. A short overview of today's electrode problems and solutions is followed by the presentation of a new pyrocarbon tip lead. The new tip material and the conception of the lead allow an increase in energy transfer efficiency and a retention of good sensing properties. Clinical experience confirms theoretical expectations. New methods for tissue reaction limitation are under evaluation.

Initial results with an activated pyrolytic carbon tip electrode.

The initial results acquired from testing of a new activated pyrocarbon electrode for cardiac pacing are presented. In vitro testing has shown energy efficiency to be higher than for platinum electrodes. Histologic examination of implanted leads in animals has demonstrated a less significant tissue reaction at the tip. Finally, in a clinical trial of 121 patients with these leads, strength-duration curves have low rheobase values. Chronic thresholds are often consistently low. These reports suggest very satisfactory results with this pyrolytic carbon electrode.

[Measurement of the myocardial stimulation threshold in chronic and acute patients with pacemaker implanted (author's transl)]. / Misura della soglia di elettrostimolazione cardiaca in pazienti portatori di pacemaker, acuti e cronici.

Eighty-two patients, with electrodes implanted for varying periods of time, have been divided into three groups: acute (at implantation); intermediate (3 to 36 months) and chronic (37 to 124 months). In these groups, respectively 28, 26 and 28 myocardial stimulation threshold measurements have been performed. Measurements have been performed with MEEMR (Myocardial Excitation Energy Meter), an instrument deviced and built by the Institute of Elaboration of Information, CNR and University of Pisa. Microjoule has been chosen as unit of measure. More commonly used units of measure, such as threshold current in milliamp, have been calculated from values in microjoules. Mean values was 0.6 muJ in the first group, 6.9 muJ in the second one and 8.3 in the third one. Student test has been performed on such measurements, divided into groups, with the following results: p less than 0.01 between 1st and 2nd group, non significant difference between 2nd and 3rd group, p less than 0.01 between 1st and 3rd group. Such results suggest a trend toward myocardial threshold stabilization over a long period of time, as had already been hypothized by others Authors. Further useful information may be drawn from these data if they are evaluated in relation to a life-time pacemaker, as is nowadays desirable in view of recent progress in circuit technology and energy sources.